(Circulation. 2003;107:2577.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From Brigham and Womens Hospital, Harvard Medical School, Boston, Mass (M.A.P., E.B.); the University of Toronto, Ontario, Canada (D.L., J.L.R.); the University of Pennsylvania Medical Center, Philadelphia (M.S.J.S., T.P.); and the University of Arizona, Tucson (S.G.).
Correspondence to Martin St John Sutton, FRCP, Director of Cardiac Imaging Program, Division of Cardiology, University of Pennsylvania Medical Center, Gates Bldg, 3400 Spruce St, Philadelphia, PA 19104. E-mail suttonm{at}mail.med.upenn.edu
Background The relation between left ventricular (LV) remodeling and ventricular arrhythmias after myocardial infarction is poorly documented. We investigated the relations between LV size, hypertrophy, and function and ventricular arrhythmias in 263 patients from the Survival and Ventricular Enlargement (SAVE) study, using quantitative 2D echocardiography and ambulatory ECG monitoring after myocardial infarction.
Methods and Results Transthoracic 2D echocardiograms and arrhythmia monitoring were performed at baseline (mean, 11 days) and 1 and 2 years after infarction. LV size, short-axis muscle (mass) area (LVMA), and function were quantified from 2D echocardiograms. The prevalence of ventricular tachycardia (VT) and frequent ventricular ectopy (premature ventricular contractions [PVCs] >10/h) was assessed from ambulatory ECG. VT and PVCs >10/h occurred in 20% and 29% of patients at baseline, in 22% and 35% at 1 year and 23% and 39% at 2 years, respectively. VT and PVCs >10/h at baseline and 1 and 2 years were significantly related to LV size, LVMA, and function. Furthermore, changes in LV size and function from baseline to 2 years predicted both VT and PVCs >10/h. The study was underpowered to detect treatment effect of ACE inhibitors and ß-adrenergic receptor blockers but did not alter the relations between ventricular arrhythmias, LV size, and function.
Conclusions Quantitative echocardiographic assessment of LV size, LVMA, and function and changes in these measurements over time predict ventricular arrhythmias after infarction. Altered LV architecture and function during postinfarction LV remodeling provide an important substrate for triggering high-grade ventricular arrhythmias.
Key Words: remodeling arrhythmia myocardial infarction echocardiography
Related Article:
Circulation 2003 107: 2531-2532.
This article has been cited by other articles:
![]() |
E Wu, J T Ortiz, P Tejedor, D C Lee, C Bucciarelli-Ducci, P Kansal, J C Carr, T A Holly, D Lloyd-Jones, F J Klocke, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study Heart, June 1, 2008; 94(6): 730 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. St John Sutton Quest for Diastolic Prognostic Indicators of Clinical Outcome After Acute Myocardial Infarction Circulation, May 20, 2008; 117(20): 2570 - 2572. [Full Text] [PDF] |
||||
![]() |
C. L. del Rio, P. I. McConnell, M. Kukielka, R. Dzwonczyk, B. D. Clymer, M. B. Howie, and G. E. Billman Electrotonic remodeling following myocardial infarction in dogs susceptible and resistant to sudden cardiac death J Appl Physiol, February 1, 2008; 104(2): 386 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Pfeffer and E. D. Frohlich Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2021 - H2025. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Hudson, P. W. Armstrong, W. Ruzyllo, J. Brum, L. Cusmano, P. Krzeski, R. Lyon, M. Quinones, P. Theroux, D. Sydlowski, et al. Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) Trial J. Am. Coll. Cardiol., July 4, 2006; 48(1): 15 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Hohnloser Ventricular Arrhythmias: Antiadrenergic Therapy for the Patient with Coronary Artery Disease Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S23 - S31. [Abstract] [PDF] |
||||
![]() |
H. U. Klein and S. Reek "The Older the Broader": Electrogram Characteristics Help Identify the Critical Isthmus During Catheter Ablation of Postinfarct Ventricular Tachycardia J. Am. Coll. Cardiol., August 16, 2005; 46(4): 675 - 677. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, K. Swedberg, Writing Committee:, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. A. Smiseth, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur. Heart J., June 1, 2005; 26(11): 1115 - 1140. [Full Text] [PDF] |
||||
![]() |
P. A. Grayburn, C. P. Appleton, A. N. DeMaria, B. Greenberg, B. Lowes, J. Oh, J. F. Plehn, P. Rahko, M. St. John Sutton, E. J. Eichhorn, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: The Beta-blocker Evaluation of Survival Trial (BEST) J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1064 - 1071. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Solomon, D. Wang, P. Finn, H. Skali, L. Zornoff, J. J.V. McMurray, K. Swedberg, S. Yusuf, C. B. Granger, E. L. Michelson, et al. Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program Circulation, October 12, 2004; 110(15): 2180 - 2183. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Nerheim, S. Birger-Botkin, L. Piracha, and B. Olshansky Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia Circulation, July 20, 2004; 110(3): 247 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hole, C. Hall, and T. Skjaerpe N-terminal proatrial natriuretic peptide predicts two-year remodelling in patients with acute transmural myocardial infarction Eur. Heart J., March 1, 2004; 25(5): 416 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Zipes Less Heart Is More Circulation, May 27, 2003; 107(20): 2531 - 2532. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |